A seasoned executive, Hoskins brings decades of experience scaling therapies, driving U.S. growth and delivering on strategic objectives. He joins the company around six months after it raised $42 million in a Series D financing round.
The Manchester, England–based company develops Phagenyx, a first-of-its-kind therapy to use pharyngeal electrical stimulation (PES). It aims to restore swallowing control in patients with severe dysphagia post-stroke. The FDA granted Phagenyx breakthrough device designation in January 2020. It is also available in Europe.
Phagenesis received FDA de novo clearance for and launched the Phagenyx system in October 2022.
Hoskins most recently served as CEO of Axon Therapies, which develops a novel denervation technology for treating heart failure. Before that, he led commercial strategy for Outset Medical. Hoskins also spent time as DVP of Heart Failure Therapies at Abbott.
“Loss of swallowing function after a stroke can be physically and emotionally devastating for patients and costly for providers to manage. Phagenyx’s non-surgical, implant-free approach to restoring swallowing function significantly improves patient quality of life and reduces the cost and complexity of care for providers,” said Hoskins. “I am thrilled and honored to build on the early success of the company as we enter this next phase of global growth and expand our partnership with clinicians who have so few options to improve the clinical outcomes and quality of life for their patients with dysphagia.”
